Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TRDA - Entrada Therapeutics Inc

IEX Last Trade
17.74
0.240   1.353%

Share volume: 177,913
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%
$17.50
0.24
1.37%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 26%
Dept financing 12%
Liquidity 54%
Performance 38%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
7.14%
1 Month
4.73%
3 Months
13.24%
6 Months
36.26%
1 Year
9.53%
2 Year
52.19%
Key data
Stock price
$17.74
P/E Ratio 
6.30
DAY RANGE
$17.08 - N/A
EPS 
$3.05
52 WEEK RANGE
$10.75 - $18.17
52 WEEK CHANGE
$0.15
MARKET CAP 
658.432 M
YIELD 
N/A
SHARES OUTSTANDING 
37.200 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
1.56
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$115,503
AVERAGE 30 VOLUME 
$137,541
Company detail
CEO:
Region: US
Website:
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.

Recent news